Source:http://linkedlifedata.com/resource/pubmed/id/18984894
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
17
|
pubmed:dateCreated |
2008-11-5
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1538-3598
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
5
|
pubmed:volume |
300
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2051-3
|
pubmed:meshHeading | |
pubmed:year |
2008
|
pubmed:articleTitle |
Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point?
|
pubmed:affiliation |
Division of Endocrinology, Diabetes and Metabolism, Medical Genetics Institute, Cedars-Sinai Medical Center, and Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|